Division of Cardiac Surgery, Department of Surgery, Medical University of Vienna, Vienna, Austria.
Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
J Thorac Cardiovasc Surg. 2021 Sep;162(3):803-811. doi: 10.1016/j.jtcvs.2020.01.083. Epub 2020 Feb 19.
The implantation of rapid-deployment aortic valves may interfere with the conduction system of the heart. This study evaluates the occurrence and predictive factors of conduction anomalies in patients undergoing surgical aortic valve replacement (SAVR) with a rapid-deployment balloon-expandable bioprosthesis in a single-center, real-world experience.
Between May 2010 and April 2019, 700 consecutive patients were included in a prospective, ongoing database with a longitudinal follow-up preoperatively, at discharge, and at 3 months, 1 year, 3 years, and 5 years postoperatively. Thirty-seven patients (5.3%) had a permanent pacemaker at baseline and were excluded from further analysis, leaving 663 patients for analysis. Assessment of conduction anomalies was performed by electrocardiography (ECG) monitoring and repeated 12-lead ECG during the hospital stay and at postoperative follow-ups.
Preoperatively, 126 patients (19.0%) presented with different conduction disturbances. New permanent pacemaker implantation (PPI) occurred in 61 patients during the first 14 days (cumulative incidence, 9.4%). The indication for PPI was complete atrioventricular block in 47 cases (77%). Preoperative conduction anomalies, such as right bundle branch block, as well as operative characteristics (concomitant procedures) were found to be independent predictors for new PPI. One-year survival was 98% in patients with new early PPI and 96% in those without new early PPI (P = .60).
The PPI rate was in the range of previous reports for rapid-deployment prostheses. PPI did not have a significant influence on short- to intermediate-term survival. Case selection with exclusion of patients presenting with baseline conduction disturbances may decrease the rate of new PPIs after SAVR with rapid-deployment balloon-expandable bioprostheses.
快速部署主动脉瓣的植入可能会干扰心脏的传导系统。本研究评估了在单中心真实世界经验中,使用快速部署球囊扩张生物瓣进行外科主动脉瓣置换术(SAVR)的患者中传导异常的发生和预测因素。
2010 年 5 月至 2019 年 4 月期间,连续 700 例患者被纳入前瞻性、正在进行的数据库,进行术前、出院时以及术后 3 个月、1 年、3 年和 5 年的纵向随访。37 例(5.3%)患者在基线时具有永久性起搏器,因此被排除在进一步分析之外,其余 663 例患者进行分析。通过心电图(ECG)监测和住院期间及术后随访时重复 12 导联 ECG 评估传导异常。
术前,126 例患者(19.0%)存在不同程度的传导障碍。在最初的 14 天内,有 61 例患者发生新的永久性起搏器植入(累计发生率 9.4%)。永久性起搏器植入的指征为 47 例(77%)完全性房室传导阻滞。术前传导异常,如右束支传导阻滞,以及手术特征(合并手术)被发现是新的永久性起搏器植入的独立预测因素。新发生早期永久性起搏器植入的患者 1 年生存率为 98%,无新发生早期永久性起搏器植入的患者为 96%(P = 0.60)。
永久性起搏器植入率与先前快速部署假体的报告一致。永久性起搏器植入对短期至中期生存没有显著影响。选择不伴有基线传导障碍的患者进行病例筛选可能会降低使用快速部署球囊扩张生物瓣进行 SAVR 后新发生永久性起搏器植入的发生率。